ShenZhou Cell (688520.SH) Finolimab and Bevacizumab monoclonal antibody have received acceptance of market application.

On January 17th, according to the official website of CDE, the market application for the approval of the combination therapy of Shen Zhou Cell's (688520.SH) PD1 blocking antibody, Finoxumab (SCT-I10A), and Bevacizumab (SCT510) for the first-line treatment of liver cancer has been accepted. Finoxumab is a functional monoclonal antibody developed by Shen Zhou Cell that targets PD-1. By blocking the binding of PD-1 to its ligand, it increases the supply of T-cells and inflammatory cytokines at the tumor site, reduces the proportion of regulatory T-cells and myeloid-derived suppressor cells in the tumor microenvironment, and changes the tumor microenvironment, thereby restoring and enhancing the immune cytotoxicity of T-cells and inhibiting tumor growth. In November 2023, the market application of this product for the treatment of head and neck squamous cell carcinoma has been accepted by CDE. In addition, Bevacizumab is a recombinant humanized anti-VEGF monoclonal antibody independently developed by Shen Zhou Cell. It specifically binds to VEGF, blocking its interaction with its receptor, reducing neovascularization, inducing regression of existing blood vessels, inhibiting tumor growth. Originally known as Avastin, this product has been approved in China in June 2023 for the treatment of metastatic colorectal cancer, advanced, metastatic, or recurrent non-small cell lung cancer, recurrent glioblastoma, hepatocellular carcinoma, epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, and cervical cancer.